Study #2022-0817
Master protocol for the Phase 1 study of cell therapies for the treatment of patients with relapsed or refractory Acute Myeloid Leukemia or high-risk Myelodysplastic Syndrome, Including long-term safety follow-up
MD Anderson Study Status
Not Accepting
Treatment Agent
SPRX002, ARC-T Cells
Description
The purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study phase:
Phase I
Physician name:
Naval Daver
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.